Skip to main content
Clinical Trials/DRKS00030018
DRKS00030018
Completed
Phase 4

Management of split-thickness skin graft donor site: An open, prospective, randomized, controlled clinical trial for comparison of three different dressing materials.

QRSKIN GmbH0 sites69 target enrollmentAugust 15, 2022

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Split-skin grafting donor sites
Sponsor
QRSKIN GmbH
Enrollment
69
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 15, 2022
End Date
April 25, 2020
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
QRSKIN GmbH

Eligibility Criteria

Inclusion Criteria

  • patients scheduled for elective skin grafting were eligible for inclusion in the study

Exclusion Criteria

  • age under 18 years, pregnancy / lactation, local infection at planned split\-thickness skin grafting donor site, hypersensitivity to dressing components, malignant or autoimmune disease, vasculitis, connective tissue diseases, immune system disorders, chemo\-, radio\- and immunosuppressive therapy within 30 days prior to study enrolment, systemic corticosteroids (intake \> 10mg/day), drug abuse, excessive alcohol consumption, recent participation in other clinical trials within 4 weeks before study enrolment.

Outcomes

Primary Outcomes

Not specified

Similar Trials